Eckert & Ziegler SE (ETR:EUZ)

Market Cap	771.57M -30.8%
Revenue (ttm)	312.50M +4.4%
Net Income	49.74M +35.7%
EPS	0.79 +36.4%
Shares Out	62.58M
PE Ratio	15.51
Forward PE	14.91
Dividend	0.22 (1.78%)
Ex-Dividend Date	Jun 25, 2026

Volume	28,178
Open	12.31
Previous Close	12.33
Day's Range	12.24 - 12.49
52-Week Range	12.01 - 18.26
Beta	1.47
Analysts	Strong Buy
Price Target	21.60 (+74.76%)
Earnings Date	Nov 12, 2026

About Eckert & Ziegler SE

Eckert & Ziegler SE manufactures and sells isotope technology components in Europe, North America, Asia, and internationally. It operates through two segments, Medical and Isotope Products. The company provides small implants for the treatment of prostate cancer seeds based on iodine-125; and eye applicators based on ruthenium-106 and iodine-125 for the treatment of choroidal melanomas; brain seed, HDR and brachytherapy; therapeutic and radiotherapy accessories, X-Ray therapy, GA-68 generators, radiochromatography, hot cells; and radiopharmaceu...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 1992
• Employees: 1,105
• Stock Exchange: Deutsche Börse Xetra
• Ticker Symbol: EUZ

Financial Performance

In 2025, Eckert & Ziegler SE's revenue was 311.96 million, an increase of 5.45% compared to the previous year's 295.85 million. Earnings were 48.76 million, an increase of 46.54%.

Analyst Summary

According to 3 analysts, the average rating for EUZ stock is "Strong Buy." The 12-month stock price target is €21.60, which is an increase of 74.76% from the latest price.

Price Target

€21.60

(74.76% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Oct 2, 2026

Data Sources Report a data error